Market Overview

Achieve Life Sciences Reports 74-80% Median Reduction In Smoking In Study

Achieve Life Sciences Reports 74-80% Median Reduction In Smoking In Study

Achieve Life Sciences Inc (NASDAQ: ACHV) a company focused on nicotine addiction, announced positive results Tuesday from the ORCA-1 dose-selection trial of cytisinicline for smoking cessation.

The primary endpoint was the reduction in daily smoking, a self-reported measure.

Across all treatment arms, subjects on cytisinicline experienced a 74-80-percent median reduction in the number of cigarettes smoked over a 25-day treatment period — compared to a 62-percent reduction in the placebo arms. 

Achieve Life Sciences shares were trading down by 5.67 percent to $3.42 after the open Tuesday. 

Related Links:

Slack's IPO: What You Need To Know

7 Stocks To Watch For June 11, 2019

Posted-In: smoking tobaccoBiotech News General Best of Benzinga


Related Articles (ACHV)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

10 Biggest Price Target Changes For Tuesday

Apollo Global Acquires Shutterfly: 2 Analyst Takes